Cap Innov'Est 2

RDS is a healthcare technology startup focused on remote patient monitoring solutions. Its flagship product, MultiSense®, is a high-precision, multi-parametric monitoring system that enables healthcare professionals to continuously track patients' physiological parameters in both hospital and home settings. This innovative, multi-patented device combines a wearable monitor with a cloud platform, transforming collected data into actionable clinical insights. RDS targets hospitals, particularly surgical departments, seeking to enhance patient care and reduce hospital stays through early discharge and continuous monitoring, ultimately contributing to significant healthcare savings. The MultiSense® solution is CE marked (MDR) and is available in several European countries. RDS operates on a recurring revenue model through a "fee for service" approach, offering training and support to healthcare professionals for effective implementation. The company's commitment to improving patient pathways has been recognized with multiple awards and validation from completed clinical investigations, supported by a skilled international team with extensive expertise in healthcare and medical devices.

VistaCare Medical is a French company specializing in the development, manufacturing, and distribution of innovative medical devices designed to treat acute and chronic wounds. The company focuses on non-contact wound treatment within a controlled environment, which enhances patient care and significantly reduces treatment times and hospital stays. VistaCare's technology aims to improve the quality of life for patients suffering from complex wounds and provides caregivers with tools to simplify their daily tasks. By addressing critical therapeutic needs, such as isolating nosocomial risks and enabling visual monitoring of wound progression, VistaCare facilitates personalized care tailored to the specific type and stage of each wound, ultimately advancing the standard of wound management.

Opencell is a company founded in 2015, building on an open source telco billing project initiated in 2007. It specializes in providing an integrated revenue management platform designed to manage subscription and usage-based billing across various industries, including telecommunications, cloud services, IoT, and utilities. The platform addresses the limitations of both complex legacy billing systems and simplistic SaaS solutions, offering a more flexible and agile monetization approach. With over 40 successful implementations worldwide, Opencell's open-source solution enables organizations to efficiently administer their subscription and usage-based revenues, making sophisticated billing accessible to a diverse range of businesses.

Defymed is a leading innovator in the development of implantable medical devices that enhance drug delivery systems across various therapeutic applications. The company focuses on site-specific delivery of therapeutics to minimize adverse events associated with current standard care, thereby improving disease management and patient quality of life. Defymed has developed two pioneering technologies: MailPan®, a device for physiologic cell encapsulation, and ExOlin®, a targeted drug delivery device currently in clinical use. With exclusive technology and expertise, Defymed's medical devices serve as a platform for multiple therapeutic applications, including type 1 diabetes, hemophilia, and cancer management. The company is certified ISO13485:2016 and has established a robust global network of experts in cell therapy and drug delivery. Defymed has received numerous accolades in Europe and the USA for its innovative approaches to enhancing patient care.

Syndivia is a biotechnology company focused on developing innovative cancer therapeutics aimed at treating patients with challenging cancer indications. The company specializes in targeted antibody-drug conjugates (ADCs), designed to optimize drug-to-antibody ratios, thereby enhancing antitumor efficacy and safety. Syndivia's vision centers on leveraging the unique properties of tumor hallmarks and the tumor microenvironment to deliver effective treatments that improve outcomes for cancer patients.

Urania Therapeutics is a biopharmaceutical company focused on the identification and development of readthrough compounds aimed at treating genetic diseases and certain cancers. The company utilizes a proprietary structure-based drug design platform to create novel therapeutic treatments that address conditions caused by mutations, specifically those involving premature stop codons during protein synthesis. By enabling the production of full-length, functional proteins, Urania Therapeutics targets a range of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its innovative approach, the company seeks to restore normal protein production, offering potential new solutions for patients with these challenging genetic conditions.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Medsenic SAS is a privately held company based in Paris, France, specializing in the development and manufacture of drugs aimed at treating autoimmune diseases, including systemic lupus erythematosus and graft-versus-host disease. Founded in 2010, the company also produces arsenic trioxide, which is utilized in the treatment of acute promyelocytic leukemia, contributing to significant remissions and potential cures for serious conditions. Medsenic focuses on innovative therapeutic solutions to address unmet medical needs in the field of autoimmune and hematological disorders.

Opencell is a company founded in 2015, building on an open source telco billing project initiated in 2007. It specializes in providing an integrated revenue management platform designed to manage subscription and usage-based billing across various industries, including telecommunications, cloud services, IoT, and utilities. The platform addresses the limitations of both complex legacy billing systems and simplistic SaaS solutions, offering a more flexible and agile monetization approach. With over 40 successful implementations worldwide, Opencell's open-source solution enables organizations to efficiently administer their subscription and usage-based revenues, making sophisticated billing accessible to a diverse range of businesses.

Inoviem Scientific SAS is a contract research biotechnology company based in Strasbourg, France, founded in 2011. The company specializes in developing advanced technologies for analyzing drug-target interactions under physiological conditions using human tissues. Its proprietary technologies include physiological intermolecular modulation spectroscopy, which examines the interactions of exogenous molecules with tissue, and techniques for isolating protein complexes and reconstructing their three-dimensional structures. Inoviem Scientific offers a range of services across the drug development spectrum, including target identification, lead optimization, preclinical and clinical development, and biomarker testing. The company serves a diverse clientele, including private and academic laboratories, as well as the pharmaceutical and biotechnology industries. By leveraging its innovative technologies, Inoviem Scientific aims to enhance the drug development process, improve the selection of lead compounds, and reduce attrition rates, ultimately accelerating the delivery of new therapeutic solutions.

PeptiMimesis is a company focused on the design, discovery, and early development of transmembrane therapeutic peptides. It employs a unique approach to identify peptidomimetic candidates that target the hetero- and homodimerization of specific receptors. The company aims to develop its pipeline around critical targets in oncology, immuno-oncology, and immune diseases. PeptiMimesis is also open to collaborations with pharmaceutical partners to explore receptors of mutual interest, enhancing the potential for innovative therapeutic solutions.

FiberMetrix specializes in innovative solutions for real-time radiation dose monitoring in both medical and industrial applications. The company develops advanced dosimetry technology that utilizes patented optical fiber technology to provide automatic feedback on radiation exposure for patients and occupational settings. Its expertise in radiation detection and dosimetry allows FiberMetrix to create a range of sensors, including fully integrated and handheld devices with variable geometry, which enable precise and remote measurement of radiation doses. These systems enhance awareness of radiation exposure and improve the safety and efficiency of clinical examinations and imaging applications across various radiation-based sectors.

Wizzvet is an innovative platform designed for veterinary telemedicine, functioning as a professional social network that fosters continuous education and collaboration within the veterinary community. The platform facilitates communication among veterinarians, allowing them to post queries and share diagnostic information, including photos, sampling results, and imaging studies. This enables practitioners, particularly those in isolated areas, to seek expert advice on complex cases. Wizzvet also offers a wide range of web conferences and online courses, introducing two to three new educational opportunities weekly, which help veterinarians earn continuing education points while enhancing their knowledge and skills.

PeptiMimesis is a company focused on the design, discovery, and early development of transmembrane therapeutic peptides. It employs a unique approach to identify peptidomimetic candidates that target the hetero- and homodimerization of specific receptors. The company aims to develop its pipeline around critical targets in oncology, immuno-oncology, and immune diseases. PeptiMimesis is also open to collaborations with pharmaceutical partners to explore receptors of mutual interest, enhancing the potential for innovative therapeutic solutions.

Opencell is a company founded in 2015, building on an open source telco billing project initiated in 2007. It specializes in providing an integrated revenue management platform designed to manage subscription and usage-based billing across various industries, including telecommunications, cloud services, IoT, and utilities. The platform addresses the limitations of both complex legacy billing systems and simplistic SaaS solutions, offering a more flexible and agile monetization approach. With over 40 successful implementations worldwide, Opencell's open-source solution enables organizations to efficiently administer their subscription and usage-based revenues, making sophisticated billing accessible to a diverse range of businesses.

Defymed is a leading innovator in the development of implantable medical devices that enhance drug delivery systems across various therapeutic applications. The company focuses on site-specific delivery of therapeutics to minimize adverse events associated with current standard care, thereby improving disease management and patient quality of life. Defymed has developed two pioneering technologies: MailPan®, a device for physiologic cell encapsulation, and ExOlin®, a targeted drug delivery device currently in clinical use. With exclusive technology and expertise, Defymed's medical devices serve as a platform for multiple therapeutic applications, including type 1 diabetes, hemophilia, and cancer management. The company is certified ISO13485:2016 and has established a robust global network of experts in cell therapy and drug delivery. Defymed has received numerous accolades in Europe and the USA for its innovative approaches to enhancing patient care.

Inoviem Scientific SAS is a contract research biotechnology company based in Strasbourg, France, founded in 2011. The company specializes in developing advanced technologies for analyzing drug-target interactions under physiological conditions using human tissues. Its proprietary technologies include physiological intermolecular modulation spectroscopy, which examines the interactions of exogenous molecules with tissue, and techniques for isolating protein complexes and reconstructing their three-dimensional structures. Inoviem Scientific offers a range of services across the drug development spectrum, including target identification, lead optimization, preclinical and clinical development, and biomarker testing. The company serves a diverse clientele, including private and academic laboratories, as well as the pharmaceutical and biotechnology industries. By leveraging its innovative technologies, Inoviem Scientific aims to enhance the drug development process, improve the selection of lead compounds, and reduce attrition rates, ultimately accelerating the delivery of new therapeutic solutions.

Bionext S.A. is a biotechnology company based in Strasbourg, France, specializing in bioinformatics and the development of advanced software tools aimed at enhancing drug discovery and development processes. Founded in 2009, Bionext focuses on creating a three-dimensional molecular visualization software that integrates big data, cloud computing, and OMICS data. This platform enables pharmaceutical and biotechnology companies to visualize and simulate drug interactions within human cells, thereby improving the understanding and prediction of drug efficacy and side effects. Additionally, Bionext offers a virtual screening platform that models cellular environments to facilitate high-throughput screening and early assessments of new compounds in pharmaceuticals, cosmetics, and agri-food sectors. The company is dedicated to addressing critical challenges in drug development, including drug profile assessment and repurposing strategies.